PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales: M., VAN DIJK, M., RAB, B., VAN OIRSCHOT, J., BOS, C., DERICHS, A., RIJNEVELD, M., CNOSSEN, E., NUR, B., BIEMOND, M., BARTELS, J., JANS, W., VAN SOLINGE, R., SCHUTGENS, R., VAN WIJK, E., VAN BEERS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Pitch Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426848/
http://dx.doi.org/10.1097/01.HS9.0000872868.40573.13
_version_ 1784778770873319424
author M., VAN DIJK
M., RAB
B., VAN OIRSCHOT
J., BOS
C., DERICHS
A., RIJNEVELD
M., CNOSSEN
E., NUR
B., BIEMOND
M., BARTELS
J., JANS
W., VAN SOLINGE
R., SCHUTGENS
R., VAN WIJK
E., VAN BEERS
author_facet M., VAN DIJK
M., RAB
B., VAN OIRSCHOT
J., BOS
C., DERICHS
A., RIJNEVELD
M., CNOSSEN
E., NUR
B., BIEMOND
M., BARTELS
J., JANS
W., VAN SOLINGE
R., SCHUTGENS
R., VAN WIJK
E., VAN BEERS
author_sort M., VAN DIJK
collection PubMed
description
format Online
Article
Text
id pubmed-9426848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94268482022-08-31 PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE M., VAN DIJK M., RAB B., VAN OIRSCHOT J., BOS C., DERICHS A., RIJNEVELD M., CNOSSEN E., NUR B., BIEMOND M., BARTELS J., JANS W., VAN SOLINGE R., SCHUTGENS R., VAN WIJK E., VAN BEERS Hemasphere Pitch Presentations Lippincott Williams & Wilkins 2022-08-16 /pmc/articles/PMC9426848/ http://dx.doi.org/10.1097/01.HS9.0000872868.40573.13 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Pitch Presentations
M., VAN DIJK
M., RAB
B., VAN OIRSCHOT
J., BOS
C., DERICHS
A., RIJNEVELD
M., CNOSSEN
E., NUR
B., BIEMOND
M., BARTELS
J., JANS
W., VAN SOLINGE
R., SCHUTGENS
R., VAN WIJK
E., VAN BEERS
PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
title PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
title_full PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
title_fullStr PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
title_full_unstemmed PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
title_short PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
title_sort pi-02: follow-up results of a phase 2 study assessing the safety and efficacy of mitapivat treatment, an oral pyruvate kinase activator, for up to 60 weeks in subjects with sickle cell disease
topic Pitch Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426848/
http://dx.doi.org/10.1097/01.HS9.0000872868.40573.13
work_keys_str_mv AT mvandijk pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT mrab pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT bvanoirschot pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT jbos pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT cderichs pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT arijneveld pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT mcnossen pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT enur pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT bbiemond pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT mbartels pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT jjans pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT wvansolinge pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT rschutgens pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT rvanwijk pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease
AT evanbeers pi02followupresultsofaphase2studyassessingthesafetyandefficacyofmitapivattreatmentanoralpyruvatekinaseactivatorforupto60weeksinsubjectswithsicklecelldisease

Ejemplares similares